SCHEDULE: Eventide Group Reports 0% Stake in VYNE Therapeutics

Eventide Asset Management and its principals have filed an amended Schedule 13G, reporting zero beneficial ownership in VYNE Therapeutics Inc. common stock.

Summary

• Eventide Asset Management, LLC, Finny Kuruvilla, M.D., Ph.D., and Robin C. John, collectively referred to as the 'Reporting Persons', have filed an Amendment No. 2 to their Schedule 13G.
• The filing indicates that as of September 30, 2025, the Reporting Persons beneficially own 0 shares of VYNE Therapeutics Inc. Common Stock.
• This represents 0% of the class of securities.
• The Reporting Persons disclaim beneficial ownership of the securities covered by this statement.
• The filing certifies that the securities were not acquired or held for the purpose of changing or influencing control of VYNE Therapeutics Inc.

Sentiment

Score: 5

Explanation: The filing is a neutral, factual disclosure of a change in beneficial ownership to 0%, with no positive or negative implications for the issuer's operational or financial performance.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding VYNE Therapeutics Inc.'s future outlook.

Management Comments

• The Reporting Persons certify that, to the best of their knowledge and belief, the securities referred to were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.

Industry Context

This filing is a routine disclosure of institutional ownership changes and does not provide specific insights into broader industry trends or competitive landscape for VYNE Therapeutics Inc. It primarily reflects a change in a specific investor's position.

Stakeholder Impact

• Shareholders: Indicates that a previously significant institutional holder (or group) no longer holds a reportable stake, which could be interpreted as a lack of conviction or a reallocation of capital by that specific investor group. However, without context of previous holdings, the impact is minimal.

Key Dates

Keywords

VYNE Therapeutics, Eventide Asset Management, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Ownership, SEC Filing